Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter
This study is ongoing, but not recruiting participants.
Sponsored by: RMT Medical Technologies, Ltd.
Information provided by: RMT Medical Technologies, Ltd.
ClinicalTrials.gov Identifier: NCT00654979
  Purpose

To determine the safety and effectiveness of the SafeFlo filter for permanent protection against pulmonary emboli. All patients will be selected to receive the filter according to the stated inclusion / exclusion criteria after consultation between the attending physician and interventional radiologist. Patients with a permanent implantation will be followed for up to 6 months. Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of permanent filter patients considered to be a clinical success will be the primary efficacy parameter.


Condition Intervention
Pulmonary Embolism
Device: SafeFlo IVC Filter

MedlinePlus related topics: Pulmonary Embolism
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter

Further study details as provided by RMT Medical Technologies, Ltd.:

Primary Outcome Measures:
  • Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. [ Time Frame: 6 months follow-up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The proportion of patients with successful deployment of the filter will be calculated and presented with a 95% exact confidence interval. [ Time Frame: 3 and 6 months follow-up ] [ Designated as safety issue: Yes ]

Enrollment: 117
Study Start Date: July 2003
Estimated Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: SafeFlo IVC Filter
    IVC Filter
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Traditional indications for vena cava filter in patients with established DVT or PE, including (40):

    • Patients with proven Pulmonary Embolus (PE) or Deep Vein Thrombosis (DVT) and one or more of the following:

      1. Contraindication to anticoagulation
      2. Complication of anticoagulation
      3. Failure of anticoagulation

        • Recurrent PE despite adequate anticoagulation therapy
        • Inability to achieve adequate anticoagulation
      4. Poor compliance with anticoagulation medications
  • Extended indications for vena cava filter placement in patients with established DVT or PE, including the following (31, 40):

    • Large free-floating thrombus in the iliac vein or IVC;
    • Following massive PE in which recurrent emboli may prove fatal;
    • During/after surgical or transcatheter embolectomy;
    • Filter placement in high-risk trauma and orthopedic patients:
  • High risk trauma or orthopedic patients who cannot receive anticoagulation because of increased bleeding risk, and have one or more of the following injury patterns (31, 40):

    1. Severe closed head injury (GCS < 8);
    2. Incomplete spinal cord injury with para or quadriplegia;
    3. Complex pelvic fractures with associated long-bone fractures;
    4. Multiple long bone fractures.
  • Patients undergoing long-term immobilization (e.g., ICU or Surgical oncology)

Exclusion Criteria:

  • All patients under 18 years of age.
  • All patients undergoing emergency procedures.
  • All patients with abnormal IVC anatomy or pathology of the IVC such as thrombosis or tumor which prevent safe filter implantation.
  • All patients with an IVC diameter which precludes oversizing of the filter platform.
  • All patients with active infection / bacteremia.
  • All patients with sensitivity to contrast media.
  • Uncorrectable severe coagulopathy (e.g., patients with liver or multisystem failure).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00654979

Locations
United States, New Jersey
Holy Name Hospital
Teaneck, New Jersey, United States
United States, New York
Montefiore Medical Center
Bronx, New York, United States
Mt. Sinai Hospital
Manhattan, New York, United States
Austria
University Hospital Vienna
Vienna, Austria
Greece
251 Air Force Hospital
Athens, Greece
Israel
Rabin Medical Center
Petach Tikva, Israel
South Africa
Universitas Hospital
Bloemfontein, South Africa
United Kingdom, Scotland
Queen Margaret Hospital
Dumfermline, Scotland, United Kingdom
Sponsors and Collaborators
RMT Medical Technologies, Ltd.
  More Information

Sponsor Website  This link exits the ClinicalTrials.gov site

Responsible Party: RMT Medical Technologies, Ltd. ( Aaron Feldman, CEO )
Study ID Numbers: SFF-104
Study First Received: March 30, 2008
Last Updated: April 3, 2008
ClinicalTrials.gov Identifier: NCT00654979  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Embolism and Thrombosis
Pulmonary Embolism
Respiratory Tract Diseases
Embolism
Lung Diseases
Vascular Diseases
Thrombosis

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009